SuanFarma-Header SuanFarma-Header


Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type


            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): K13

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: K13

            Highest Development Status: Phase I Product Type: Peptide

            Partner/Sponsor/Collaborator: Yabao Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement September 15, 2015


            Yabao receives exclusive rights to develop and commercialize innovative products targeting PTEN nuclear translocation for the treatment of stroke in China, Taiwan and Hong Kong while Primary Peptides retains rights in all other markets.